Calliditas Therapeutics (CALTX.ST) Stock Analysis & AI Equity Report
Calliditas Therapeutics (CALTX.ST) overview
Calliditas Therapeutics (CALTX.ST) stock analysis and AI equity research. For the latest completed financial year, 2023, Calliditas Therapeutics reported revenue of SEK 1,207m and operating profit of SEK -384m; the year-end share price was 127.10 SEK and market capitalisation was SEK 6,822m. Calliditas Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Calliditas Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-05. Data will be refreshed during report generation.
About Calliditas Therapeutics
Calliditas Therapeutics develops and commercializes medicines for rare diseases, with an initial focus on renal and hepatic conditions. Its lead products include TARPEYO/Kinpeygo, budesonide delayed-release capsules for primary IgA nephropathy, and it also advances partnered regional licenses and additional pipeline candidates. In 2024, Asahi Kasei acquired control of the company.
Generate the Calliditas Therapeutics report
Calliditas Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Calliditas Therapeutics and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.